2013 Fiscal Year Final Research Report
Relation cMet and Topoisomerase I in lung cancer
| Project/Area Number |
23501306
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Clinical oncology
|
|---|
| Research Institution | Kanazawa University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Keywords | 肺癌 / cMet / Toposioemrase I / 分子標的治療 |
|---|
| Research Abstract |
Personalized therapy progresses in the treatment of the lung cancer. cMet is important as a drug-resistant factor for the EGFR tyrosine kinase inhibitor. DNA topoisomerase I (TopoI) is necessary for replication of DNA and is a target enzyme of irinotecan. We focused on the relation between these two protein . cMet up-regulate expression of TopoI in lung cancer cell lines, and we showed that it prescribed sensitivity of irinotecan, a TopoI inhibitor. Furthermore, We showed that TopoI correlated to Met protein in the tumor sample of the lung cancer patients and that cMet protein was the prognostic factor.
As for this study, it is significant for progress of the personalized therapy for lung cancer treatment.
|
-
-
[Journal Article] Transformation to small-cell lung cancer following treatment with EGFR tyrosine kinase inhibitors in a patient with lung adenocarcinoma2013
Author(s)
Watanabe S, Sone T, Matsui T, Yamamura K, Tani M, Okazaki A, Kurokawa K, Tambo Y, Takato H, Ohkura N, Waseda Y, Katayama N, Kasahara K
-
Journal Title
Lung Cancer
Volume: 82, 2
Pages: 370-372
DOI
Peer Reviewed
-
-
-
-
